106 related articles for article (PubMed ID: 21628978)
1. [Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor].
Kakuta H
Yakugaku Zasshi; 2011; 131(6):917-23. PubMed ID: 21628978
[TBL] [Abstract][Full Text] [Related]
2. Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
Ohsawa F; Morishita K; Yamada S; Makishima M; Kakuta H
ACS Med Chem Lett; 2010 Dec; 1(9):521-5. PubMed ID: 24900241
[TBL] [Abstract][Full Text] [Related]
3. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
Fujii S; Ohsawa F; Yamada S; Shinozaki R; Fukai R; Makishima M; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5139-42. PubMed ID: 20656484
[TBL] [Abstract][Full Text] [Related]
4. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
Takamatsu K; Takano A; Yakushiji N; Morohashi K; Morishita K; Matsuura N; Makishima M; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 May; 3(5):780-7. PubMed ID: 18297677
[TBL] [Abstract][Full Text] [Related]
5. RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects.
Kawata K; Morishita K; Nakayama M; Yamada S; Kobayashi T; Furusawa Y; Arimoto-Kobayashi S; Oohashi T; Makishima M; Naitou H; Ishitsubo E; Tokiwa H; Tai A; Kakuta H
J Med Chem; 2015 Jan; 58(2):912-26. PubMed ID: 25486327
[TBL] [Abstract][Full Text] [Related]
6. Modulation of RXR function through ligand design.
Pérez E; Bourguet W; Gronemeyer H; de Lera AR
Biochim Biophys Acta; 2012 Jan; 1821(1):57-69. PubMed ID: 21515403
[TBL] [Abstract][Full Text] [Related]
7. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Leibowitz MD; Ardecky RJ; Boehm MF; Broderick CL; Carfagna MA; Crombie DL; D'Arrigo J; Etgen GJ; Faul MM; Grese TA; Havel H; Hein NI; Heyman RA; Jolley D; Klausing K; Liu S; Mais DE; Mapes CM; Marschke KB; Michellys PY; Montrose-Rafizadeh C; Ogilvie KM; Pascual B; Rungta D; Tyhonas JS; Urcan MS; Wardlow M; Yumibe N; Reifel-Miller A
Endocrinology; 2006 Feb; 147(2):1044-53. PubMed ID: 16269450
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Mukherjee R; Davies PJ; Crombie DL; Bischoff ED; Cesario RM; Jow L; Hamann LG; Boehm MF; Mondon CE; Nadzan AM; Paterniti JR; Heyman RA
Nature; 1997 Mar; 386(6623):407-10. PubMed ID: 9121558
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice.
Kakuta H; Ohsawa F; Yamada S; Makishima M; Tai A; Yasui H; Yoshikawa Y
Biol Pharm Bull; 2012; 35(4):629-33. PubMed ID: 22466572
[TBL] [Abstract][Full Text] [Related]
10. Retinoid X Receptor Ligands with Anti-Type 2 Diabetic Activity.
Morishita KI; Kakuta H
Curr Top Med Chem; 2017; 17(6):696-707. PubMed ID: 27320332
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats.
Ogasawara A; Murakami Y; Yakushiji N; Ohsawa F; Kusaba J; Aiba T; Kurosaki Y; Kakuta H
Drug Dev Ind Pharm; 2011 Sep; 37(9):1060-7. PubMed ID: 21417609
[TBL] [Abstract][Full Text] [Related]
12. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
Yamamoto A; Kakuta H; Sugimoto Y
Int Immunopharmacol; 2014 Sep; 22(1):204-8. PubMed ID: 24975659
[TBL] [Abstract][Full Text] [Related]
13. Retinoid X receptor ligands: a patent review (2007 - 2013).
Yamada S; Kakuta H
Expert Opin Ther Pat; 2014 Apr; 24(4):443-52. PubMed ID: 24456080
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
Ohsawa F; Yamada S; Yakushiji N; Shinozaki R; Nakayama M; Kawata K; Hagaya M; Kobayashi T; Kohara K; Furusawa Y; Fujiwara C; Ohta Y; Makishima M; Naitou H; Tai A; Yoshikawa Y; Yasui H; Kakuta H
J Med Chem; 2013 Mar; 56(5):1865-77. PubMed ID: 23391145
[TBL] [Abstract][Full Text] [Related]
15. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
Kotani H; Tanabe H; Mizukami H; Amagaya S; Inoue M
Biol Pharm Bull; 2012; 35(1):1-9. PubMed ID: 22223330
[TBL] [Abstract][Full Text] [Related]
16. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
17. Fluorescent retinoid X receptor ligands for fluorescence polarization assay.
Yamada S; Ohsawa F; Fujii S; Shinozaki R; Makishima M; Naitou H; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5143-6. PubMed ID: 20667726
[TBL] [Abstract][Full Text] [Related]
18. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo.
Cesario RM; Klausing K; Razzaghi H; Crombie D; Rungta D; Heyman RA; Lala DS
Mol Endocrinol; 2001 Aug; 15(8):1360-9. PubMed ID: 11463859
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Yamauchi T; Waki H; Kamon J; Murakami K; Motojima K; Komeda K; Miki H; Kubota N; Terauchi Y; Tsuchida A; Tsuboyama-Kasaoka N; Yamauchi N; Ide T; Hori W; Kato S; Fukayama M; Akanuma Y; Ezaki O; Itai A; Nagai R; Kimura S; Tobe K; Kagechika H; Shudo K; Kadowaki T
J Clin Invest; 2001 Oct; 108(7):1001-13. PubMed ID: 11581301
[TBL] [Abstract][Full Text] [Related]
20. Retinoid X receptor agonists modulate Foxp3⁺ regulatory T cell and Th17 cell differentiation with differential dependence on retinoic acid receptor activation.
Takeuchi H; Yokota-Nakatsuma A; Ohoka Y; Kagechika H; Kato C; Song SY; Iwata M
J Immunol; 2013 Oct; 191(7):3725-33. PubMed ID: 23980207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
